Seelos Therapeutics Stock Forecast, Price & News

-0.02 (-0.38 %)
(As of 04/16/2021 04:00 PM ET)
Today's Range
Now: $5.26
50-Day Range
MA: $4.20
52-Week Range
Now: $5.26
Volume2.65 million shs
Average Volume9.21 million shs
Market Capitalization$411.77 million
P/E RatioN/A
Dividend YieldN/A
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 2016 and is headquartered in New York, NY.
Seelos Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SEEL
Phone(646) 293-2100
Year FoundedN/A



Sales & Book Value

Annual Sales$380,000.00


Net Income$-51,260,000.00


Market Cap$411.77 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable


Why Seelos Therapeutics Stock Is Skyrocketing Today
March 20, 2021 |
Midday Market Update: What Stocks Are Up Today?
March 20, 2021 |
4 Hot Penny Stocks To Watch Before Next Week
March 12, 2021 |
See More Headlines


Overall MarketRank

1.30 out of 5 stars

Medical Sector

816th out of 2,024 stocks

Pharmaceutical Preparations Industry

387th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.02 (-0.38 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SEEL News and Ratings via Email

Sign-up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions

Is Seelos Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Seelos Therapeutics stock.
View analyst ratings for Seelos Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Seelos Therapeutics?

Wall Street analysts have given Seelos Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Seelos Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Seelos Therapeutics' next earnings date?

Seelos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Seelos Therapeutics

How has Seelos Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Seelos Therapeutics' stock was trading at $0.78 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SEEL shares have increased by 574.4% and is now trading at $5.26.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SEEL?

3 analysts have issued 1 year price targets for Seelos Therapeutics' stock. Their forecasts range from $12.00 to $15.00. On average, they expect Seelos Therapeutics' share price to reach $13.67 in the next year. This suggests a possible upside of 159.8% from the stock's current price.
View analysts' price targets for Seelos Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Seelos Therapeutics' key executives?

Seelos Therapeutics' management team includes the following people:
  • Raj Mehra, Chairman, President, CEO & Chief Financial Officer
  • Jessica Kardish, Vice President-Clinical Development & Operations
  • Lucas Pilipski, Executive Director-Clinical Operations
  • Tim Whitaker, Chief Medical Officer
  • Gopal Krishna, Head-Manufacturing & Technical Operations

Who are some of Seelos Therapeutics' key competitors?

What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK).

What is Seelos Therapeutics' stock symbol?

Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."

How do I buy shares of Seelos Therapeutics?

Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seelos Therapeutics' stock price today?

One share of SEEL stock can currently be purchased for approximately $5.26.

How much money does Seelos Therapeutics make?

Seelos Therapeutics has a market capitalization of $411.77 million and generates $380,000.00 in revenue each year.

How many employees does Seelos Therapeutics have?

Seelos Therapeutics employs 8 workers across the globe.

What is Seelos Therapeutics' official website?

The official website for Seelos Therapeutics is

Where are Seelos Therapeutics' headquarters?

Seelos Therapeutics is headquartered at 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022.

How can I contact Seelos Therapeutics?

Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at (646) 293-2100 or via email at [email protected]

This page was last updated on 4/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.